Ophthalmology
In line with Distribution Contract with S.I.F.I. S.p.A. (SIFI) (Italy) signed in March 2014, NovaMedica has obtained exclusive rights for commercialization of ophthalmological portfolio products in Russia and CIS. More information about the agreement ...
Currently, this segment of NovaMedica’s portfolio is represented by the following products:
 |
ColbiocinTM – eye ointment, combined antimicrobial Rx product for local administration in ophthalmology. |
 |
Mirtilene ForteTM – capsules with high concentration of active ingredients (blueberry anthocyanosides), facilitate improvement of functional state of eye retina in patients with myopia, diabetes and night vision adaptation disorder. The product improves sensitivity to light intensity changes, facilitates vision acuity improvement and night vision adaptation, and facilitates improvement of retina blood supply. Indications: moderate and severe myopia, acquired hemeralopia, diabetic retonopathy, night vision adaptation disorder (night and twilight vision), muscular asthenopia, Junius-Kuhnt central atherosclerotic retinal degeneration, tapetoretina degeneration (pigmentary degeneration of retina). |
All products passed Clinical Trials and registered in Russia.
PRODUCTS HAVE CONTRAINDICATIONS. PLEASE CONSULT A SPECIALIST BEFORE USE
The Ophthalmology segment of NovaMedica’s portfolio also includes the following product:
 |
Proluxa® – complex containing lutein and the strong natural antioxidant epigallocatechin gallate, green tea extract. |
DIETARY SUPPLEMENT. NOT A PHARMACEUTICAL DRUG
Shareholders
Pipeline
Media Center
-
FDA Publishes COVID-19 Pandemic Recovery and Preparedness Plan Summary Report
18 January 2021
-
Research How a gene linked to the circadian clock could point to new prostate cancer treatments
18 January 2021
-
2021 in Focus: Pharm Exec’s Annual Industry Outlook
15 January 2021
-
Research Eye stem cell transplant to treat blindness bolsters retinal function in monkeys
15 January 2021